Prevalence of factors associated with poor outcomes of hospitalized myasthenia gravis patients in Thailand

References

1. ↵
   1. MacDonald BK,
   2. Cockerell OC,
   3. Sander JW,
   4. Shorvon SD

   (2000) The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 123, 665–676.
2. ↵
   1. Tiamkao S

   (2007) Myasthenia Gravis. J North-Eastern Neurosci 2, 21–29.
3. ↵
   1. Turner C

   (2007) A review of myasthenia gravis: Pathogenesis, clinical features and treatment. Curr Anaes Crit Care 18, 15–23.
4. ↵
   1. Sharma S,
   2. Lal V,
   3. Prabhakar S,
   4. Agarwal R

   (2013) Clinical profile and outcome of myasthenic crisis in a tertiary care hospital: A prospective study. Ann Indian Acad Neurol 16, 203–207.
5. ↵
   1. Alshekhlee A,
   2. Miles JD,
   3. Katirji B,
   4. Preston DC,
   5. Kaminski HJ

   (2009) Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72, 1548–1554.
6. ↵
   1. Lai CH,
   2. Tseng HF

   (2010) Nationwide population-based epidemiological study of myasthenia gravis in Taiwan. Neuroepidemiology 35, 66–71.
7. 1. Oopik M,
   2. Kaasik AE,
   3. Jakobsen J

   (2003) A population-based epidemiological study on myasthenia gravis in Estonia. J Neurol Neurosurg Psychiatry 74, 1638–1643.
8. ↵
   1. Gattellari M,
   2. Goumas C,
   3. Worthington JM

   (2012) A national epidemiological study of Myasthenia Gravis in Australia. Eur J Neurol 19, 1413–1420.
9. ↵
   1. Carr AS,
   2. Cardwell CR,
   3. McCarron PO,
   4. McConville J

   (2010) A systematic review of population- based epidemiological studies in myasthenia gravis. BMC Neurol 10, 46.
10. ↵
    1. World Health Organization

    (2006) Neurological disorders: Public health challenges (WHO, Geneva (CH)) Available from: http://www.who.int/mental_health/neurology/neurological_disorders_report_web.pdf.
11. ↵
    1. Guptill JT,
    2. Sharma BK,
    3. Marano A,
    4. Soucy A,
    5. Krueger A,
    6. Sanders DB

    (2012) Estimated cost of myasthenia gravis in an insured U.S. population. Muscle Nerve 45, 363–366.
12. ↵
    1. Mao ZF,
    2. Mo XA,
    3. Qin C,
    4. Lai YR,
    5. Hackett ML

    (2012) Incidence of thymoma in myasthenia gravis: a systematic review. J Clin Neurol 8, 161–169.
13. ↵
    1. Sieb JP

    (2014) Myasthenia gravis: an update for the clinician. Clin Exp Immunol 175, 408–418.